Search Results for: drug patents

Two page summary: What does the TPP do as regards prices of drugs and other medical technologies?

Posted on by Claire Cassedy

Attached is a 2 page summary of the main provisions in the Trans-Pacific Partnership Agreement (TPP) that will lead to higher prices for drugs and other medical technologies.

A pdf version of the note is available here: /wp-content/uploads/KEI-TPP-Briefing-2015-2-A2M.pdf

What does the TPP do as regards prices of drugs and other medical technologies?

KEI TPP Briefing note 2015:2
June 10, 2015
Continue Reading →

Put the patents at risk, not the patients

Posted on by James Love

The TPP, following a plethora of other trade agreements involving the United States, the European Union and Japan as trading partners, seeks to expand and extend drug monopolies, by requiring lower standards for the grant of patents, extensions of patent terms, exclusive rights in test data, among other measures. These proposals and polices are designed to have the predictable effect of making drug prices higher.

Continue Reading →

Uncategorized

Letter from Senator Bernie Sanders to the VA, asking for compulsory licenses on Hepatitis C drugs.

Posted on by KEI Staff

Attached is the text of a letter sent by Senator Bernie Sanders to Robert A. McDonald, the Secretary, U.S. Department of Veterans Affairs, asking the Secretary “to use your authority as Secretary of Veterans Affairs to break the patents on Hepatitis C medications for the treatment of veterans suffering with the disease.”

Continue Reading →

State of California considers AB463, a bill to require disclosure of drug development costs, and more economic data

Posted on by James Love

This is a bill that will see legislative action next week in California, and the bill has some momentum. This is the first time I have seen any government make an effort to have useful data on the economics drug drug development and pricing, and it provides a model that other governments may want to built upon.

A mark-up on the bill has been scheduled for Tuesday, April 21, 2015, in the Assembly Health Committee.

BILL NUMBER: AB 463
INTRODUCED BILL TEXT

INTRODUCED BY Assembly Member Chiu

FEBRUARY 23, 2015

Continue Reading →

Uncategorized

KEI’s supplemental comments in USTR 301: Online pharmacies, parallel trade and counterfeit drugs

Posted on by James Love

At the February 24, 2015 USTR hearing on Special 301, KEI asked to provide supplemental comments on R&D for the record, and KEI was separately asked by USTR to provide comments on online pharmacies, and by DHHS to comment on the relationship between emergencies and compulsory licensing. (The KEI page on Special 301 is here: /ustr/special301).

Continue Reading →

Uncategorized

WIPO patent committee (SCP21): Intervention of KEI on Patents and Health

Posted on by Thiru

The following intervention on patents and health was delivered by KEI during the 21st session on WIPO’s Standing Committee on the Law of Patents (SCP). Part 1 was delivered on 4 November 2014 during discussions of the Feasibility Study on the Disclosure of International Nonproprietary Names (INN) in Patent Applications and/or Patents. Part 2 was delivered on 5 November 2014 during general discussions on patents and health.

Statement of Knowledge Ecology International (KEI)

Item 7: Patents and health

Part 1

Continue Reading →

Uncategorized